Enhanced radiosensitization and chemosensitization in NF-κ B-suppressed human oral cancer cells via the inhibition of γ-irradiation- and 5-FU-induced production of IL-6 and IL-8

International Journal of Cancer

Volumn 108, Issue 6, 2004, Pages 912-921

  Tamatani, Tetsuya ^a   Azuma, Masayuki ^a   Ashida, Yuki ^a   Motegi, Katsumi ^a   Takashima, Rina ^a   Harada, Koji ^a   Kawaguchi, Shin Ichi ^a   Sato, Mitsunobu ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

5 FU; Cytokines; MMP 9; NF B; Oral cancer cells; y irradiation

Indexed keywords

FLUOROURACIL; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8; LIPOCORTIN 5; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CARCINOGENICITY; CHEMOSENSITIVITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GAMMA IRRADIATION; GENETIC TRANSFECTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; INHIBITION KINETICS; MOUSE; MOUTH CARCINOMA; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOSENSITIZATION; TUMOR GROWTH;

ANIMALS; ANNEXIN A5; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA; CELL DIVISION; CELL NUCLEUS; CELL SEPARATION; CULTURE MEDIA, CONDITIONED; CYTOSOL; DNA, COMPLEMENTARY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FLUOROURACIL; GAMMA RAYS; GENETIC VECTORS; HUMANS; I-KAPPA B PROTEINS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-6; INTERLEUKIN-8; LUCIFERASES; MATRIX METALLOPROTEINASE 9; MICE; MICE, NUDE; MOUTH NEOPLASMS; MUTATION; NEOVASCULARIZATION, PATHOLOGIC; NF-KAPPA B; OLIGONUCLEOTIDES; TIME FACTORS; TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 1642539107     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11640     Document Type: Article

References (36)

1. Vaux DL, Korsmeyer SJ. Cell death in development. Cell 1999;96:245-54.
2. Fulda S, Susin S, Kroemer G, Debatin K-M. Molecular ordering of apoptosis induced by anticancer drugs in neuroblastoma cells. Cancer Res 1998;58:4453-60.
3. Baldwin AS Jr. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB. J Clin Invest 2001;107:241-6.
4. Wang C-Y, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS Jr. NF-κB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 1998;281:1680-3.
5. Baeuerle PA. Pro-inflammatory signaling: last pieces in the NF-κB puzzle? Curr Biol 1998;8: R19-R22.
6. Waddick KG, Uckun FM. Innovative treatment programs against cancer: II. Nucleas factor-κB (NF-κB) as a molecular target. Biochem Pharmacol 1999;57:9-17.
7. Duffey DC, Chen Z, Dong G, Ondrey FG, Wolf JS, Brown K, Siebenlist U, Van Waes C. Expression of a dominant-negative mutant inhibitorκBα of nuclear factor-κB in human head and neck squamous cell carcinoma inhibits survival, proinflammatory cytokine expression, and tumor growth in vivo. Cancer Res 1999;59:3468-74.
8. Huang S, Robinson JB, DeGuzman A, Bucana CD, Fidler IJ. Blockade of nuclear factor- κB signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin 8. Cancer Res 2000;60:5334-9.
9. Smith CW, Chen Z, Dong G, Loukinova E, Van Waes C. The host environment promotes the development of primary and metastatic squamous cell carcinomas that constitutively express proinflammatory cytokines IL-1α, IL-6, GM-CSF and KC. Clin Exp Metastais 1998;16:655-64.
10. Koch AE, Polverini PJ, Kunkel SL, Harlow LA, DiPietro LA, Elner VM, Elner SG, Strieter RM. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 1992;258:1798-801.
11. Dong G, Chen Z, Kato T, Van Waes C. The host environment promotes the constitutive activation of nuclear factor-κB and proinflammatory cytokine expression during metastatic tumor progression of murine squamous cell carcinoma. Cancer Res 1999;59:3495-504.
12. Sato H, Seiki M. Regulatory mechanism of 92 kDa type IV collagenase gene expression which is associated with invasiveness of tumor cells. Oncogene 1993;8:395-405.
13. Wolf JS, Chen Z, Dong G, Sunwoo JB, Bancroft CC, Cape DE, Yeh NT, Mukaido N, Van Waes C. IL (Interleukin)-1α promotes nuclear factor-κB and AP-1-induced IL-8 expression, cell survival, and proliferation in head and neck squamous cell carcinoma. Clin Cancer Res 2001;7:1812-20.
14. Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM. Suppression of TNF-α- induced apoptosis by NF-κB. Science 1994;274:787-9.
15. Wang C-Y, Cusack JC Jr, Liu R, Baldwin AS Jr. Control of inducible chemoresistance: Enhanced antitumor therapy through increased apoptosis by inhibition of NF-κB. Nat Med 1999;4:412-7.
16. Clark JR, Frei E III. Chemotherapy for head and neck cancer: progress and controversy in the management of patients with MO disease. Semin Oncol 1989;16:44-57.
17. Azuma M, Motegi K, Aota K, Yamashita T, Yoshida H, Sato M. TGF-Β1 inhibits NF-κB activity through induction of IκB-α expression in human salivary gland cells: A possible mechanism of growth suppression by TGF-β1. Exp Cell Res 1999:250:213-22.
18. Tamatani T, Azuma M, Aota K, Yamashita T, Bando T, Sato M. Enhanced 1κB kinase activity is responsible for the augmented activity of NF-κB in human head and neck carcinoma cells. Cancer Lett 2001;171:165-72.
19. Traenckner EB-M, Pahl HL, Henkel T, Schmidt KN, Wilk S, Baeuerle PA. Phosphorylation of human IKB-α proteolysis and NF-κB activation in response to diverse stimuli. EMBO J 1995;14:2876-83.
20. Imbert V, Rupec RA, Livolsi A, Pahl HL, Traenckner EB-M, Mueller-Dieckmann C, Farahifar D, Rossi B, Auberger P, Baeuerle PA, Peyron J-F. Tyrosine phosphorylation of IκB-α activates NF-κB without proteolytic degradation. Cell 1996;86:787-98.
21. Cusack JC Jr, Liu R, Baldwin AS Jr. Inducible chemoresistance to 7-ethyl-10- [4-(1-piperidino)-l-piperidino]-carbonyloxycamptotethecin (CPT-11) in colorectal cancer cells and a xenograft model is overcome by inhibition of nuclear factor-κB activation. Cancer Res 2000;60:2323-30.
22. Cusack JC Jr, Liu R, Houston M, Abendroth K, Elliott PJ. Adams J, Baldwin AS Jr. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-κB inhibition. Cancer Res 2001;61:3535-40.
23. Azuma M, Tamatani T, Ashida Y, Takashima R, Harada K, Sato M. Cisplatin induces apoptosis in oral squamous carcinoma cells by the mitochondria-mediated but not the NF- κB-suppressed pathway. Oral Oncol 2003;39:282-9.
24. Curry HA, Clemens RA, Shah S, Bradbury CM, Botero A, Spitz DR, Goswami P, Gius D. Heat shock inhibits radiation-induced activation of NF-κB via inhibition of the I-κB kinase complex. J Biol Chem 1999;274:23061-7.
25. Bradbury CM, Markovina S, Wei SJ, Rene LM, Zoberi I, Horikoshi N, Gius D. Indomethacin-induced radiosensitization and inhibition of ionizing radiation-induced NF-KB activation in HeLa cells occur via a mechanism involving p38 MAP kinase. Cancer Res 2001;61:7689-96.
26. Aota K, Azuma M, Tamatani T, Yamashita T, Ashida Y, Sato M. Stable inhibition of NF- κB in salivary gland cells does not enhance sensitivity to TNF-α-induced apoptosis due to upregulation of TRAF-1 expression. Exp Cell Res 2002;276:111-9.
27. Gorski DH, Beckett MA, Jaskowiak NT, Calvin DP, Mauceri HJ, Salloum RM, Seetharam S, Koons A, Hari DM, Kufe DW, Weichselbaum RR. Blockade of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 1999;59:3374-8.
28. Andela VB, Schwarz EM, Puzas JE, O'Keefe RJ, Rosier RN. Tumor metastasis and the reciprocal regulation of prometastatic and anti-metastatic factors by nuclear factor KB. Cancer Res 2000;60:6557-62.
29. Wakisaka N, Murono S, Yoshizaki T, Furukawa M, Pagano JS. Epstein-Barr virus latent membrane protein 1 induces and causes release of fibroblast growth factor-2. Cancer Res 2002;62:6337-44.
30. Azuma M, Yuki T, Motegi K, Sato M. Enhancement of bFGF export associated with malignant progression of human salivary gland cell clones. Int J Cancer 1997;71:891-6.
31. De Larco JE, Wuertz BRK, Manivel JC, Furcht LT. Progression and enhancement of metastatic potential after exposure of tumor cells to chemotherapeutic agents. Cancer Res 2001;61:2857-61.
32. Conze DC, Weiss L, Regen PS, Bhushan A, Weaver D, Johnson P, Rincon, M. Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells. Cancer Res 2001;61:8851-8.
33. Dendorfer U, Oettgen P, Libermann TA. Multiple regulatory elements in the interleukin-6 gene mediate induction by prostaglandins, cyclic AMP, and lipopolysaccharide. Mol Cell Biol 1994;14:4443-54.
34. Mukaido N, Okamoto S, Ishikawa Y, Matsushima K. Molecular mechanism of interleukin-8 gene expression. J Leukocyte Biol 1994;56:554-8.
35. Bailly S, Fay M, Israel N, Gougerot-Pocidalo MA. The transcription factor AP-1 binds to the human interleukin 1α promoter. Eur Cytokine Netw 1996;7:125-8.
36. Thomas RS, Tymms MJ, McKinlay LH, Shannon MF, Seth A, Kola I. ETS1, NFκB and AP1 synergistically transactivate the human GM-CSF promoter. Oncogene 1997;14:2845-55.